Login Register Cart 0
Generic placeholder image

Current Cardiology Reviews

Editor-in-Chief

ISSN (Print): 1573-403X
ISSN (Online): 1875-6557

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Redefining the Roles of Aspirin across the Spectrum of Cardiovascular Disease Prevention

Author(s): Matthew T. Brown*, Kristina S. Bortfeld, Laurence S. Sperling and Nanette K. Wenger

Volume 19, Issue 6, 2023

Published on: 26 May, 2023

Article ID: e020523216449 Pages: 14

DOI: 10.2174/1573403X19666230502163828

Price: $65

Abstract

Even before its role in platelet inhibition was fully characterized in the 1980s, aspirin had been incorporated into the cardiovascular disease care algorithm. Early trials examining its use in unstable angina and acute myocardial infarction revealed evidence of its protective role in the secondary prevention of atherosclerotic cardiovascular disease (ASCVD). Large trials assessing use in the primary prevention setting and optimal dosing regimens were studied in the late 1990s and early 2000s. As a cornerstone of cardiovascular care, aspirin was incorporated into primary and secondary ASCVD prevention guidelines in the United States and mechanical heart valve guidelines. However, in recent years, with significant advances in medical and interventional ASCVD therapies, scrutiny has been placed on the bleeding profile of aspirin, and guidelines have adapted to new evidence. Updates in primary prevention guidelines reserve aspirin only for patients at higher ASCVD risk and low bleeding risk - though questions remain in ASCVD risk assessment as risk-enhancing factors have proven difficult to incorporate on a population level. New thoughts regarding aspirin use in secondary prevention - especially with the concomitant use of anticoagulants - have altered recommendations as additional data accrued. Finally, a recommendation for aspirin and vitamin K antagonists with mechanical heart valves has been modified. Despite aspirin losing a foothold in cardiovascular care, new evidence has strengthened claims for its use in women at high risk for preeclampsia.

Graphical Abstract

[1]
Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: Executive summary: A report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation 2019; 140(11): e563-95.
[http://dx.doi.org/10.1161/CIR.0000000000000677] [PMID: 30879339]
[2]
American Diabetes Association 10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes—2021. Diabetes Care 2021; 44 (Suppl. 1): S125-50.
[http://dx.doi.org/10.2337/dc21-S010] [PMID: 33298421]
[3]
Davidson KW, Barry MJ, Mangione CM, et al. Aspirin use to prevent cardiovascular disease. JAMA 2022; 327(16): 1577-84.
[http://dx.doi.org/10.1001/jama.2022.4983] [PMID: 35471505]
[4]
Chiarito M, Sanz-Sánchez J, Cannata F, et al. Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. Lancet 2020; 395(10235): 1487-95.
[http://dx.doi.org/10.1016/S0140-6736(20)30315-9] [PMID: 32386592]
[5]
Koo BK, Kang J, Park KW, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): An investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet 2021; 397(10293): 2487-96.
[http://dx.doi.org/10.1016/S0140-6736(21)01063-1] [PMID: 34010616]
[6]
Massel DR, Little SH. Antiplatelet and anticoagulation for patients with prosthetic heart valves. Cochrane Database Syst Rev 2013; 2013(7): CD003464.
[PMID: 23839768]
[7]
Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2021; 143(5): e72-e227.
[PMID: 33332150]
[8]
Davidson KW, Barry MJ, Mangione CM, et al. Aspirin use to prevent preeclampsia and related morbidity and mortality. JAMA 2021; 326(12): 1186-91.
[http://dx.doi.org/10.1001/jama.2021.14781] [PMID: 34581729]
[9]
Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk. J Am Coll Cardiol 2014; 63(25) (25 Pt B): 2935-59.
[http://dx.doi.org/10.1016/j.jacc.2013.11.005] [PMID: 24239921]
[10]
Abdelaziz HK, Saad M, Pothineni NVK, et al. Aspirin for primary prevention of cardiovascular events. J Am Coll Cardiol 2019; 73(23): 2915-29.
[http://dx.doi.org/10.1016/j.jacc.2019.03.501] [PMID: 31196447]
[11]
Thobani A, Dhindsa DS, DeMoss BD, et al. Usefulness of aspirin for primary prevention of atherosclerotic cardiovascular disease. Am J Cardiol 2019; 124(11): 1785-9.
[http://dx.doi.org/10.1016/j.amjcard.2019.08.040] [PMID: 31590909]
[12]
Wenger NK. Female-friendly focus: 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Clin Cardiol 2019; 42(8): 706-9.
[http://dx.doi.org/10.1002/clc.23218] [PMID: 31211428]
[13]
Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42(34): 3227-337.
[http://dx.doi.org/10.1093/eurheartj/ehab484] [PMID: 34458905]
[14]
Steering Committee of the Physicians’ Health Study Research Group Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989; 321(3): 129-35.
[http://dx.doi.org/10.1056/NEJM198907203210301] [PMID: 2664509]
[15]
Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352(13): 1293-304.
[http://dx.doi.org/10.1056/NEJMoa050613] [PMID: 15753114]
[16]
Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988; 296(6618): 313-6.
[http://dx.doi.org/10.1136/bmj.296.6618.313] [PMID: 3125882]
[17]
The Medical Research Council’s General Practice Research Framework Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998; 351(9098): 233-41.
[http://dx.doi.org/10.1016/S0140-6736(97)11475-1] [PMID: 9457092]
[18]
Roncaglioni MC. Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general Practice. Lancet 2001; 357(9250): 89-95.
[http://dx.doi.org/10.1016/S0140-6736(00)03539-X] [PMID: 11197445]
[19]
Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): A randomised, double-blind, placebo-controlled trial. Lancet 2018; 392(10152): 1036-46.
[http://dx.doi.org/10.1016/S0140-6736(18)31924-X] [PMID: 30158069]
[20]
Bowman L, Mafham M, Wallendszus K, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 2018; 379(16): 1529-39.
[http://dx.doi.org/10.1056/NEJMoa1804988] [PMID: 30146931]
[21]
McNeil JJ, Nelson MR, Woods RL, et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med 2018; 379(16): 1519-28.
[http://dx.doi.org/10.1056/NEJMoa1803955] [PMID: 30221595]
[22]
McNeil JJ, Wolfe R, Woods RL, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med 2018; 379(16): 1509-18.
[http://dx.doi.org/10.1056/NEJMoa1805819] [PMID: 30221597]
[23]
Force USPST. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 150(6): 396-404.
[http://dx.doi.org/10.7326/0003-4819-150-6-200903170-00008] [PMID: 19293072]
[24]
Guirguis-Blake JM, Evans CV, Perdue LA, Bean SI, Senger CA. Aspirin use to prevent cardiovascular disease and colorectal cancer. JAMA 2022; 327(16): 1585-97.
[http://dx.doi.org/10.1001/jama.2022.3337] [PMID: 35471507]
[25]
Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease BMJ 2008; 337((oct16 2)): a1840.
[http://dx.doi.org/10.1136/bmj.a1840] [PMID: 18927173]
[26]
Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: A randomized controlled trial. JAMA 2008; 300(18): 2134-41.
[http://dx.doi.org/10.1001/jama.2008.623] [PMID: 18997198]
[27]
Fowkes FG, Price JF, Stewart MC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: A randomized controlled trial. JAMA 2010; 303(9): 841-8.
[http://dx.doi.org/10.1001/jama.2010.221] [PMID: 20197530]
[28]
Ikeda Y, Shimada K, Teramoto T, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: A randomized clinical trial. JAMA 2014; 312(23): 2510-20.
[http://dx.doi.org/10.1001/jama.2014.15690] [PMID: 25401325]
[29]
Chasman DI, Shiffman D, Zee RYL, et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis 2009; 203(2): 371-6.
[http://dx.doi.org/10.1016/j.atherosclerosis.2008.07.019] [PMID: 18775538]
[30]
Trinder M, Uddin MM, Finneran P, Aragam KG, Natarajan P. Clinical utility of lipoprotein(a) and LPA genetic risk score in risk prediction of incident atherosclerotic cardiovascular disease. JAMA Cardiol 2020; 6(3): 1-9.
[PMID: 33021622]
[31]
Lacaze P, Bakshi A, Riaz M, et al. Aspirin for primary prevention of cardiovascular events in relation to lipoprotein(a) genotypes. J Am Coll Cardiol 2022; 80(14): 1287-98.
[http://dx.doi.org/10.1016/j.jacc.2022.07.027] [PMID: 36175048]
[32]
Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351(9118): 1755-62.
[http://dx.doi.org/10.1016/S0140-6736(98)04311-6] [PMID: 9635947]
[33]
Dehmer SP, O’Keefe LR, Evans CV, Guirguis-Blake JM, Perdue LA, Maciosek MV. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Modeling Study for the US Preventive Services Task Force. JAMA 2022; 327(16): 1598-607.
[http://dx.doi.org/10.1001/jama.2022.3385]
[34]
Desborough MJR, Keeling DM. The aspirin story-From willow to wonder drug. Br J Haematol 2017; 177(5): 674-83.
[http://dx.doi.org/10.1111/bjh.14520] [PMID: 28106908]
[35]
Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983; 309(7): 396-403.
[http://dx.doi.org/10.1056/NEJM198308183090703] [PMID: 6135989]
[36]
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2(8607): 349-60.
[PMID: 2899772]
[37]
Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ 1994; 308(6921): 81-106.
[http://dx.doi.org/10.1136/bmj.308.6921.81] [PMID: 8298418]
[38]
Collaboration AT. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324(7329): 71-86.
[http://dx.doi.org/10.1136/bmj.324.7329.71] [PMID: 11786451]
[39]
Smith SC Jr, Blair SN, Bonow RO, et al. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. J Am Coll Cardiol 2001; 38(5): 1581-3.
[http://dx.doi.org/10.1016/S0735-1097(01)01682-5] [PMID: 11691544]
[40]
Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006; 113(19): 2363-72.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.106.174516] [PMID: 16702489]
[41]
Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update. Circulation 2011; 124(22): 2458-73.
[http://dx.doi.org/10.1161/CIR.0b013e318235eb4d] [PMID: 22052934]
[42]
Mehta SR, Yusuf S, Peters RJG, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358(9281): 527-33.
[http://dx.doi.org/10.1016/S0140-6736(01)05701-4] [PMID: 11520521]
[43]
Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345(7): 494-502.
[http://dx.doi.org/10.1056/NEJMoa010746] [PMID: 11519503]
[44]
Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002; 288(19): 2411-20.
[http://dx.doi.org/10.1001/jama.288.19.2411] [PMID: 12435254]
[45]
Lorenz RL, Schacky CV, Weber M, et al. Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily). Effects on platelet aggregation and thromboxane formation. Lancet 1984; 1(8389): 1261-4.
[http://dx.doi.org/10.1016/S0140-6736(84)92446-2] [PMID: 6144975]
[46]
Mangano DT. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002; 347(17): 1309-17.
[http://dx.doi.org/10.1056/NEJMoa020798] [PMID: 12397188]
[47]
Turpie A, Gent M, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 1993; 329(8): 524-9.
[http://dx.doi.org/10.1056/NEJM199308193290802] [PMID: 8336751]
[48]
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154(13): 1449-57.
[http://dx.doi.org/10.1001/archinte.1994.00420130036007] [PMID: 8018000]
[49]
Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348(9028): 633-8.
[http://dx.doi.org/10.1016/S0140-6736(96)03487-3] [PMID: 8782752]
[50]
Committee CS. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348(9038): 1329-39.
[http://dx.doi.org/10.1016/S0140-6736(96)09457-3] [PMID: 8918275]
[51]
Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340(12): 901-7.
[http://dx.doi.org/10.1056/NEJM199903253401201] [PMID: 10089183]
[52]
Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49(19): 1982-8.
[http://dx.doi.org/10.1016/j.jacc.2007.03.025] [PMID: 17498584]
[53]
Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. J Am Coll Cardiol 2016; 68(10): 1082-115.
[http://dx.doi.org/10.1016/j.jacc.2016.03.513] [PMID: 27036918]
[54]
Chichareon P, Modolo R, Collet C, et al. Efficacy and safety of stents in ST-segment elevation myocardial infarction. J Am Coll Cardiol 2019; 74(21): 2572-84.
[http://dx.doi.org/10.1016/j.jacc.2019.09.038] [PMID: 31753202]
[55]
Madhavan MV, Kirtane AJ, Redfors B, et al. Stent-related adverse events >1 year after percutaneous coronary intervention. J Am Coll Cardiol 2020; 75(6): 590-604.
[http://dx.doi.org/10.1016/j.jacc.2019.11.058] [PMID: 32057373]
[56]
Lip GYH, Collet JP, Haude M, Huber K. Management of antithrombotic therapy in AF patients presenting with ACS and/or undergoing PCI. Eur Heart J 2018; 39(31): 2847-50.
[http://dx.doi.org/10.1093/eurheartj/ehy396] [PMID: 30137444]
[57]
Dewilde WJM, Oirbans T, Verheugt FWA, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial. Lancet 2013; 381(9872): 1107-15.
[http://dx.doi.org/10.1016/S0140-6736(12)62177-1] [PMID: 23415013]
[58]
Fiedler KA, Maeng M, Mehilli J, et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation. J Am Coll Cardiol 2015; 65(16): 1619-29.
[http://dx.doi.org/10.1016/j.jacc.2015.02.050] [PMID: 25908066]
[59]
Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016; 375(25): 2423-34.
[http://dx.doi.org/10.1056/NEJMoa1611594] [PMID: 27959713]
[60]
Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after pci in atrial fibrillation. N Engl J Med 2017; 377(16): 1513-24.
[http://dx.doi.org/10.1056/NEJMoa1708454] [PMID: 28844193]
[61]
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37(38): 2893-962.
[http://dx.doi.org/10.1093/eurheartj/ehw210] [PMID: 27567408]
[62]
Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J 2018; 39(3): 213-60.
[http://dx.doi.org/10.1093/eurheartj/ehx419] [PMID: 28886622]
[63]
Angiolillo DJ, Goodman SG, Bhatt DL, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention. Circulation 2018; 138(5): 527-36.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.034722] [PMID: 30571525]
[64]
Angiolillo DJ, Bhatt DL, Cannon CP, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: A North American perspective: 2021 update. Circulation 2021; 143(6): 583-96.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.120.050438] [PMID: 33555916]
[65]
O’Donoghue ML, Murphy SA, Sabatine MS. The safety and efficacy of aspirin discontinuation on a background of a P2Y 12 inhibitor in patients after percutaneous coronary intervention. Circulation 2020; 142(6): 538-45.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.120.046251] [PMID: 32551860]
[66]
Knijnik L, Fernandes M, Rivera M, et al. Meta-analysis of duration of dual antiplatelet therapy in acute coronary syndrome treated with coronary stenting. Am J Cardiol 2021; 151: 25-9.
[http://dx.doi.org/10.1016/j.amjcard.2021.04.014] [PMID: 34049672]
[67]
Tomaniak M, Chichareon P, Onuma Y, et al. Benefit and risks of aspirin in addition to ticagrelor in acute coronary syndromes. JAMA Cardiol 2019; 4(11): 1092-101.
[http://dx.doi.org/10.1001/jamacardio.2019.3355] [PMID: 31557763]
[68]
Watanabe H, Domei T, Morimoto T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI. JAMA 2019; 321(24): 2414-27.
[http://dx.doi.org/10.1001/jama.2019.8145] [PMID: 31237644]
[69]
Hahn JY, Song YB, Oh JH, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention. JAMA 2019; 321(24): 2428-37.
[http://dx.doi.org/10.1001/jama.2019.8146] [PMID: 31237645]
[70]
Kim BK, Hong SJ, Cho YH, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome. JAMA 2020; 323(23): 2407-16.
[http://dx.doi.org/10.1001/jama.2020.7580] [PMID: 32543684]
[71]
Baber U, Dangas G, Angiolillo DJ, et al. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. Eur Heart J 2020; 41(37): 3533-45.
[http://dx.doi.org/10.1093/eurheartj/ehaa670] [PMID: 33085967]
[72]
Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021; 42(14): 1289-367.
[http://dx.doi.org/10.1093/eurheartj/ehaa575] [PMID: 32860058]
[73]
Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: A report of the american college of cardiology/american heart association joint committee on clinical practice guidelines. Circulation 2022; 145(3): e18-e114.
[http://dx.doi.org/10.1161/CIR.0000000000001038] [PMID: 34882435]
[74]
Jones WS, Mulder H, Wruck LM, et al. Comparative effectiveness of aspirin dosing in cardiovascular disease. N Engl J Med 2021; 384(21): 1981-90.
[http://dx.doi.org/10.1056/NEJMoa2102137] [PMID: 33999548]
[75]
Aggarwal D, Bhatia K, Chunawala ZS, et al. P2Y12 inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: Meta-analysis of randomized trials. Eur Heart JOpen 2022; 2(2): aeac019.
[http://dx.doi.org/10.1093/ehjopen/oeac019] [PMID: 35919116]
[76]
Woodward M, Lowe GDO, Francis LMA, Rumley A, Cobbe SM. A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: The CADET trial. J Thromb Haemost 2004; 2(11): 1934-40.
[http://dx.doi.org/10.1111/j.1538-7836.2004.01017.x] [PMID: 15550024]
[77]
Pettersen AÅR, Seljeflot I, Abdelnoor M, Arnesen H. High on-aspirin platelet reactivity and clinical outcome in patients with stable coronary artery disease: Results from ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial). J Am Heart Assoc 2012; 1(3): e000703.
[http://dx.doi.org/10.1161/JAHA.112.000703] [PMID: 23130135]
[78]
Gorelick PB, Farooq MU. Aspirin plus clopidogrel in acute minor ischaemic stroke or transient ischaemic attack is superior to aspirin alone for stroke risk reduction: CHANCE trial. Evid Based Med 2014; 19(2): 58.
[http://dx.doi.org/10.1136/eb-2013-101512] [PMID: 24052397]
[79]
Wang Y, Minematsu K, Wong KSL, et al. Ticagrelor in acute stroke or transient ischemic attack in asian patients. Stroke 2017; 48(1): 167-73.
[http://dx.doi.org/10.1161/STROKEAHA.116.014891] [PMID: 27899747]
[80]
Agarwal N, Mahmoud AN, Patel NK, et al. Meta-analysis of aspirin versus dual antiplatelet therapy following coronary artery bypass grafting. Am J Cardiol 2018; 121(1): 32-40.
[http://dx.doi.org/10.1016/j.amjcard.2017.09.022] [PMID: 29122278]
[81]
Schunkert H, Boening A, von Scheidt M, et al. Randomized trial of ticagrelor vs. aspirin in patients after coronary artery bypass grafting: the TiCAB trial. Eur Heart J 2019; 40(29): 2432-40.
[http://dx.doi.org/10.1093/eurheartj/ehz185] [PMID: 31145798]
[82]
Leonardi S, Franzone A, Piccolo R, et al. Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY). BMJ Open 2019; 9(3): e026053.
[http://dx.doi.org/10.1136/bmjopen-2018-026053] [PMID: 30852547]
[83]
Beyersdorf F, Vahanian A, Milojevic M, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur J Cardiothorac Surg 2021; 60(4): 727-800.
[http://dx.doi.org/10.1093/ejcts/ezab389] [PMID: 34453161]
[84]
Ussia GP, Scarabelli M, Mulè M, et al. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. Am J Cardiol 2011; 108(12): 1772-6.
[http://dx.doi.org/10.1016/j.amjcard.2011.07.049] [PMID: 21907949]
[85]
Rodés-Cabau J, Masson JB, Welsh RC, et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve. JACC Cardiovasc Interv 2017; 10(13): 1357-65.
[http://dx.doi.org/10.1016/j.jcin.2017.04.014] [PMID: 28527771]
[86]
Zuo W, Yang M, He Y, Hao C, Chen L, Ma G. Single or dual antiplatelet therapy after transcatheter aortic valve replacement: an updated systemic review and meta-analysis. J Thorac Dis 2019; 11(3): 959-68.
[http://dx.doi.org/10.21037/jtd.2019.01.87] [PMID: 31019786]
[87]
ElGuindy A. PARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients. Glob Cardiol Sci Pract 2016; 2016(4): e201633.
[PMID: 31463304]
[88]
Dangas GD, Tijssen JGP, Wöhrle J, et al. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med 2020; 382(2): 120-9.
[http://dx.doi.org/10.1056/NEJMoa1911425] [PMID: 31733180]
[89]
Wallenburg HCS, Makovitz JW, Dekker GA, Rotmans P. Low-dose aspirin prevents pregnancy-induced hypertension and pre-eclampsia in angiotensin-sensitive primigravidae. Lancet 1986; 327(8471): 1-3.
[http://dx.doi.org/10.1016/S0140-6736(86)91891-X] [PMID: 2867260]
[90]
Benigni A, Gregorini G, Frusca T, et al. Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy-induced hypertension. N Engl J Med 1989; 321(6): 357-62.
[http://dx.doi.org/10.1056/NEJM198908103210604] [PMID: 2664523]
[91]
Schiff E, Peleg E, Goldenberg M, et al. The use of aspirin to prevent pregnancy-induced hypertension and lower the ratio of thromboxane A2 to prostacyclin in relatively high risk pregnancies. N Engl J Med 1989; 321(6): 351-6.
[http://dx.doi.org/10.1056/NEJM198908103210603] [PMID: 2664522]
[92]
McParland P, Pearce JM, Chamberlain GVP. Doppler ultrasound and aspirin in recognition and prevention of pregnancy-induced hypertension. Lancet 1990; 335(8705): 1552-5.
[http://dx.doi.org/10.1016/0140-6736(90)91377-M] [PMID: 1972487]
[93]
Hauth JC, Goldenberg RL, Parker CR Jr, et al. Low-dose aspirin therapy to prevent preeclampsia. Am J Obstet Gynecol 1993; 168(4): 1083-93.
[http://dx.doi.org/10.1016/0002-9378(93)90351-I] [PMID: 8475955]
[94]
Sibai BM, Caritis SN, Thom E, et al. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. N Engl J Med 1993; 329(17): 1213-8.
[http://dx.doi.org/10.1056/NEJM199310213291701] [PMID: 8413387]
[95]
Viinikka L, Hartikainen-Sorri AL, Lumme R, Hiilesmaa V, Ylikorkala O. Low dose aspirin in hypertensive pregnant women: Effect on pregnancy outcome and prostacyclin-thromboxane balance in mother and newborn. BJOG 1993; 100(9): 809-15.
[http://dx.doi.org/10.1111/j.1471-0528.1993.tb14304.x] [PMID: 8217999]
[96]
CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group CLASP: A randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet 1994; 343(8898): 619-29.
[http://dx.doi.org/10.1016/S0140-6736(94)92633-6] [PMID: 7906809]
[97]
Caspi E, Raziel A, Sherman D, Arieli S, Bukovski I, Weinraub Z. Prevention of pregnancy-induced hypertension in twins by early administration of low-dose aspirin: a preliminary report. Am J Reprod Immunol 1994; 31(1): 19-24.
[http://dx.doi.org/10.1111/j.1600-0897.1994.tb00842.x] [PMID: 8166943]
[98]
Morris J, Fay R, Ellwood D, Cook C, Devonald K. A randomized controlled trial of aspirin in patients with abnormal uterine artery blood flow. Obstet Gynecol 1996; 87(1): 74-8.
[http://dx.doi.org/10.1016/0029-7844(95)00340-1] [PMID: 8532271]
[99]
Hermida RC, Ayala DE, Iglesias M, et al. Time-dependent effects of low-dose aspirin administration on blood pressure in pregnant women. Hypertension 1997; 30(3): 589-95.
[http://dx.doi.org/10.1161/01.HYP.30.3.589] [PMID: 9322987]
[100]
Caritis S, Sibai B, Hauth J, et al. Low-dose aspirin to prevent preeclampsia in women at high risk. N Engl J Med 1998; 338(11): 701-5.
[http://dx.doi.org/10.1056/NEJM199803123381101] [PMID: 9494145]
[101]
Rotchell YE, Cruickshank JK, Phillips Gay M, et al. Barbados Low Dose Aspirin Study in Pregnancy (BLASP): A randomised trial for the prevention of pre-eclampsia and its complications. BJOG 1998; 105(3): 286-92.
[http://dx.doi.org/10.1111/j.1471-0528.1998.tb10088.x] [PMID: 9532988]
[102]
Grab D, Paulus WE, Erdmann M, et al. Effects of low-dose aspirin on uterine and fetal blood flow during pregnancy: results of a randomized, placebo-controlled, double-blind trial. Ultrasound Obstet Gynecol 2000; 15(1): 19-27.
[http://dx.doi.org/10.1046/j.1469-0705.2000.00009.x] [PMID: 10776008]
[103]
Subtil D, Goeusse P, Puech F, et al. Aspirin (100 mg) used for prevention of pre-eclampsia in nulliparous women: The Essai Régional Aspirine Mère-Enfant study (Part 1). BJOG 2003; 110(5): 475-84.
[PMID: 12742332]
[104]
Yu CKH, Papageorghiou AT, Parra M, Palma Dias R, Nicolaides KH. Randomized controlled trial using low-dose aspirin in the prevention of pre-eclampsia in women with abnormal uterine artery Doppler at 23 weeks’ gestation. Ultrasound Obstet Gynecol 2003; 22(3): 233-9.
[http://dx.doi.org/10.1002/uog.218] [PMID: 12942493]
[105]
Villa PM, Kajantie E, Räikkönen K, et al. Aspirin in the prevention of pre-eclampsia in high-risk women: A randomised placebo-controlled PREDO Trial and a meta-analysis of randomised trials. BJOG 2013; 120(1): 64-74.
[http://dx.doi.org/10.1111/j.1471-0528.2012.03493.x] [PMID: 23126307]
[106]
Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 2017; 377(7): 613-22.
[http://dx.doi.org/10.1056/NEJMoa1704559] [PMID: 28657417]
[107]
Scazzocchio E, Oros D, Diaz D, et al. Impact of aspirin on trophoblastic invasion in women with abnormal uterine artery Doppler at 11-14 weeks: A randomized controlled study. Ultrasound Obstet Gynecol 2017; 49(4): 435-41.
[http://dx.doi.org/10.1002/uog.17351] [PMID: 27807890]
[108]
Mone F, Mulcahy C, McParland P, et al. T rial of feasibility and acceptability of routine low-dose aspirin versusE arly S creening T est indicated aspirin for pre-eclampsia prevention (TEST study): a multicentre randomised controlled trial. BMJ Open 2018; 8(7): e022056.
[http://dx.doi.org/10.1136/bmjopen-2018-022056] [PMID: 30056389]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy